{
    "2021-06-27": [
        [
            {
                "time": "",
                "original_text": "【开源医药】行业周报：关注集采下原料药企业业绩增量和医疗服务投资价值",
                "features": {
                    "keywords": [
                        "开源医药",
                        "行业周报",
                        "集采",
                        "原料药",
                        "业绩增量",
                        "医疗服务",
                        "投资价值"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "原料药",
                        "医疗服务"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "兴业证券：医药板块业绩弹性逐步释放，关注半年报业绩高增长公司",
                "features": {
                    "keywords": [
                        "兴业证券",
                        "医药板块",
                        "业绩弹性",
                        "逐步释放",
                        "半年报",
                        "高增长"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "证券时报-润灵全球2021生物医药行业ESG评级报告：较2020改善不明显",
                "features": {
                    "keywords": [
                        "证券时报",
                        "润灵全球",
                        "ESG评级",
                        "生物医药",
                        "2021",
                        "改善不明显"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}